PROANGIOGENNYE FAKTORY V SYVOROTKE KROVI I OPUKhOLI BOL'NYKh RAKOM POChKI

V V Mushtenko , P V Glybin , A V Kolpakov , A A Morozov

Medical academic journal ›› 2016, Vol. 16 ›› Issue (4) : 108 -109.

PDF
Medical academic journal ›› 2016, Vol. 16 ›› Issue (4) : 108 -109. DOI: 10.17816/MAJ164108-109
Articles
brief-report

PROANGIOGENNYE FAKTORY V SYVOROTKE KROVI I OPUKhOLI BOL'NYKh RAKOM POChKI

Author information +
History +
PDF

Abstract

Cite this article

Download citation ▾
V V Mushtenko, P V Glybin, A V Kolpakov, A A Morozov. PROANGIOGENNYE FAKTORY V SYVOROTKE KROVI I OPUKhOLI BOL'NYKh RAKOM POChKI. Medical academic journal, 2016, 16(4): 108-109 DOI:10.17816/MAJ164108-109

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Folkman J. Antiangiogenesis: new concept for therapy of solid tumors // Ann. Surg.- 1972.- Vol. 175, № 3.- P. 409-416.

[2]

Ferrara N., Gerber H. P., LeCouter J. The biology of VEGF and its receptors // Nat. Med.- 2003.- Vol. 9, № 6.- P. 669-676.

[3]

Welsh S. J., Fife K. Pazopanib for the treatment of renal cell carcinoma // Future Oncol.- 2015.- Vol. 11, № 8.- P. 1169-1179.

[4]

Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis / Iacovelli R., Sternberg C. N., Porta C., Verzoni E., de Braud F., Escudier B., Procopio G. // Curr. Drug Targets.- 2015.- Vol. 16, № 2.- P. 164-170.

[5]

Rini B. I., Small E. J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma // J. Clin. Oncol.- 2005.- Vol. 23, № 5.- P. 1028-1043.

RIGHTS & PERMISSIONS

Mushtenko V.V., Glybin P.V., Kolpakov A.V., Morozov A.A.

AI Summary AI Mindmap
PDF

38

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/